Euglycemic clamp data in the three study groups
NAFLD patients | Type 2 diabetic patients | Control subjects | |
---|---|---|---|
n | 30 | 10 | 10 |
Steady-state glucose (mmol/l) | 5.0 ± 0.3 (4.4–5.6) | 5.1 ± 0.2 (4.9–5.5) | 4.9 ± 0.2 (4.6–5.2) |
Steady-state insulin (pmol/l) | 667 ± 103 (487–940) | 722 ± 122 (581–918)* | 590 ± 55 (531–696) |
Glucose infusion rate (μmol · kg−1 · min−1) | 19.5 ± 5.7 (10.4–33.6)* | 16.2 ± 4.0 (10.8–23.2)* | 37.2 ± 9.4 (24.7–58.4) |
Glucose disposal rate (μmol · kg−1 · min−1) | 18.4 ± 5.9 (8.2–31.6)* | 18.0 ± 4.0 (13.2–26.1)* | 36.8 ± 7.6 (26.2–54.7) |
Fasting FFAs (mmol/l) | 0.67 ± 0.27 (0.26–1.30)* | 0.55 ± 0.11 (0.44–0.81)* | 0.37 ± 0.12 (0.23–0.61) |
End-of-clamp FFAs (mmol/l) | 0.21 ± 0.14 (0.05–0.55)* | 0.13 ± 0.05 (0.06–0.20)* | 0.06 ± 0.02 (0.03–0.10) |
Data are means ± SD (range).
* P < 0.001 vs. control subjects.